Lexicon Pharmaceuticals (LXRX) Return on Capital Employed (2011 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Return on Capital Employed of 11.16% for Q1 2026, up 8356.0% year-over-year from 0.13% in Q1 2025, and up 60.15% quarter-over-quarter from 28.01% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 16 years of Return on Capital Employed data on file, last reported at 11.16% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 11.16%, up 8356.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 11.16% (up 8356.0% YoY), and the FY2025 annual result was 22.15%, up 6799.0% from the prior year.
- Return on Capital Employed grew to 11.16% in Q1 2026 per LXRX's latest filing, from 28.01% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 11.16% in Q1 2026 and troughed at 94.72% in Q1 2025.
- A 5-year average of 61.18% and a median of 62.0% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed slumped 11610 bps in 2022, then jumped 8356 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 59.33% in 2022, then tumbled by 31 bps to 77.57% in 2023, then grew by 4 bps to 74.52% in 2024, then soared by 62 bps to 28.01% in 2025, then jumped by 60 bps to 11.16% in 2026.
- Business Quant data shows LXRX's Return on Capital Employed at 11.16% in Q1 2026, 28.01% in Q4 2025, and 34.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | -11.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.16% |
| Dec 31, 2025 | -28.01% |
| Sep 30, 2025 | -34.46% |
| Jun 30, 2025 | -52.19% |
| Mar 31, 2025 | -94.72% |
| Dec 31, 2024 | -74.52% |
| Sep 30, 2024 | -67.84% |
| Jun 30, 2024 | -53.63% |
| Mar 31, 2024 | -62.00% |
| Dec 31, 2023 | -77.57% |
| Sep 30, 2023 | -58.75% |
| Jun 30, 2023 | -60.28% |
| Mar 31, 2023 | -68.63% |
| Dec 31, 2022 | -59.33% |
| Sep 30, 2022 | -71.74% |
| Jun 30, 2022 | -89.10% |
| Mar 31, 2022 | -76.19% |
| Dec 31, 2021 | -65.73% |
| Sep 30, 2021 | -50.25% |
| Jun 30, 2021 | 27.01% |